MELIA (the MEtformin-LIfestyle in Antipsychotic users trial)

In the MELIA study, funded by ZonMW, we aim to optimise the application of an existing drug, metformin, for a new indication, AiWG, by examining whether metformin combined with lifestyle sessions reduces AiWG compared to placebo combined with lifestyle sessions. Furthermore, we aim to investigate the difference in reduction of AiWG between two  subgroups; clozapine use versus other antipsychotic use. At last, we aim to assess whether metformin compared to placebo improves metabolic traits, quality of life, general physical and psychological health, cost effectiveness and whether genetic liability to BMI and metabolic syndrome may help estimate weight reduction following initiation of metformin treatment. In case of reduction of AiWG due to metformin use in combination with lifestyle sessions, guidelines can implement AiWG as new indication for metformin.